CD8A and cancer: In addition, exhausted CD8+ T cells, macrophages and cancer cells, and cellular characteristics related to the responsiveness of left-sided or right-sided CRC to checkpoint inhibitor therapy were analyzed in depth to identify cell type–specific markers that are potentially applicable in clinical practice.